Acceder

Farmas USA

136K respuestas
Farmas USA
85 suscriptores
Farmas USA
Página
12.906 / 17.032
#103241

Re: Farmas USA

CEMP ahora MLNT

Con muy poco volumen pero ha llegado a hacer hasta un + 20% o tocado los 14.70 con solo 2M de share float

ahora mismo cotizando a 13.85 y abrio a 11.35.

No esta mal para ser 1er dia de cotizacion en el NASDAQ despues de la fusion. Melinta/CEMP

Cuando era solo CEMP el pasado Jueves cerro su market cap sobre los 180M los otro lo ha aportado la No Cotizada Melinta  

Tras la fusion y con el 20% que ha subido hoy ya el Market Cap se ha disparado a + 648 millones /usd pero con solo 2 M de shares float asi que este en pocos dias tendra que cambiar , o hay aqui un error

--   ------

MELINTA PARTNERSHIPS

MENARINI

Menarini.svg

In March 2017, Melinta licensed rights to delafloxacin (known as Baxdela in the U.S.) to the Menarini Group in 68 countries in Europe, Asia-Pacific, and the Commonwealth of Independent States (CIS) listed below.

Malin plc logo

In June 2015, Melinta and Malin Plc entered into an agreement for the commercialization and distribution of delafloxacin (known as Baxdela in the U.S.) in certain countries in the Middle East and Africa listed below. Under the terms of their agreement, Melinta gains access to Malin’s global network of biotechnology and pharmaceutical companies, expanding delafloxacin’s commercial potential to include the emerging nations Middle East and Africa

n January 2015, Melinta and Eurofarma Laboratórios, one of the largest pharmaceutical companies in Brazil and present in more than 20 countries in Latin America, entered into an agreement for the development and commercialization of delafloxacin (known as Baxdela in the US) in Brazil. In August 2017, the companies amended the agreement to cover all countries in Latin America. Eurofarma logon January 2015, Melinta and Eurofarma Laboratórios, one of the largest pharmaceutical companies in Brazil and present in more than 20 countries in Latin America, entered into an agreement for the development and commercialization of delafloxacin (known as Baxdela in the US) in Brazil. In August 2017, the companies amended the agreement to cover all countries in Latin America.

We have licensed solithromycin to Toyama Chemical Co., Ltd., or Toyama, for development and commercialization in Japan while retaining the rights to the rest of the world. Toyama has successfully completed a Phase 1 trial in healthy Japanese volunteers, a Phase 1 trial to measure solithromycin levels in the upper respiratory tract, and a Phase 2 trial in CABP. In December 2016, Toyama initiated Phase 3 trials in patients infected with CABP and other respiratory infections. Toyama and we are sharing the results of our respective development Toyama Logo

 

 

 

http://melinta.com/partnerships/

#103242

Re: Farmas USA

MLNT
Noooo, que siga la fiesta.

#103243

Re: Farmas USA

MLNT

A lo que dé ¿no?, jejeje.

"Buf, se me está haciendo más largo que un dia sin bolsa"

#103244

Re: Farmas USA

Mis CEMP / MLNT de momento siguen a 0 en Bankinter...🤔
A ver cuando aparecen y a que precio ....😉

#103245

Re: Farmas USA

MLNT
Para las que tengo??

#103246

Re: Farmas USA

pinta bien , yo en Ing no podia tocarlas tampoco , de momento contento

CEMP

#103247

Re: Farmas USA

OMER

Sé que la llevásteis por aquí. Cómo la veis para añadir en este momento?

#103248

Re: Farmas USA

KERX

Con un día de retraso, pero aprueban el sNDA de Auryxia

 

Te puede interesar...
  1. Inflación y tipos en el punto de mira, la historia no se repite pero rima
  2. La Euforia Post-Trump: ¿Calma o Tormenta en el Mercado?